← Leaderboards
James Alan Shayman
University Of Michigan At Ann Arbor
$8,158,958
Attributed
$10,161,354
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–19$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$10,161,354 · 6
VA$0 · 1
By mechanism
R01$7,576,724 · 3
UH3$1,534,047 · 1
UH2$631,122 · 1
R21$419,461 · 1
I01$0 · 1
Top collaborators
- Scott D Larsen8 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Bruce C. Richardson$11,674,875
- Scott D Larsen$5,478,139
- Raymond L Yung$10,907,042
- Matthew D Adams$26,174
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseLysosomal Storage DiseasesGlycosphingolipidsPhenotypeCellsPharmaceutical PreparationsEnzyme Replacement TherapySeriesPublic Health RelevanceProgramsFabry DiseaseInheritedKnockout MiceInhibitor/AntagonistCeramide GlucosyltransferaseSecondary ToCeramidesPathogenesisSignal TransductionLeadPropertyProteinsEnzymesGaucher Disease
Grant awards (32)
The Development of Small Molecule Inhibitors for Gaucher Disease Type 3$1
UH3 · FY2019 · NS · contact PI
The Development of Small Molecule Inhibitors for Gaucher Disease Type 3$1
UH3 · FY2018 · NS · contact PI
The Development of Small Molecule Inhibitors for Gaucher Disease Type 3$750,989
UH3 · FY2017 · NS · contact PI
The Development of Small Molecule Inhibitors for Gaucher Disease Type 3$783,056
UH3 · FY2016 · NS · contact PI
Mechanisms of Drug Induced Phospholipidosis$0
I01 · FY2016 · VA · contact PI
The Development of Small Molecule Inhibitors for Gaucher Disease Type 3$631,122
UH2 · FY2015 · NS · contact PI
Novel Probes for Studying Treatment of CNS-based Lysosomal Storage Diseases$589,896
R01 · FY2015 · HD
Mechanisms of Drug Induced Phospholipidosis$0
I01 · FY2015 · VA · contact PI
Novel Probes for Studying Treatment of CNS-based Lysosomal Storage Diseases$607,880
R01 · FY2014 · HD
Lysosomal Phospholipase A2 in Autoimmune Disease$319,364
R01 · FY2014 · AR · contact PI
Mechanisms of Drug Induced Phospholipidosis$0
I01 · FY2014 · VA · contact PI
Novel Probes for Studying Treatment of CNS-based Lysosomal Storage Diseases$641,847
R01 · FY2013 · HD
Lysosomal Phospholipase A2 in Autoimmune Disease$309,588
R01 · FY2013 · AR · contact PI
The Pharmacological Treatment of Fabry Disease$308,854
R01 · FY2013 · DK · contact PI
In vivo proof of efficacy studies for a novel glucosylceramide synthase inhibitor$225,086
R21 · FY2013 · NS · contact PI
Mechanisms of Drug Induced Phospholipidosis$0
I01 · FY2013 · VA · contact PI
Lysosomal phospholipase A2 in autoimmune disease$325,882
R01 · FY2012 · AR · contact PI
The Pharmacological Treatment of Fabry Disease$320,056
R01 · FY2012 · DK · contact PI
In vivo proof of efficacy studies for a novel glucosylceramide synthase inhibitor$194,375
R21 · FY2012 · NS · contact PI
Lysosomal phospholipase A2 in autoimmune disease$325,882
R01 · FY2011 · AR · contact PI
The Pharmacological Treatment of Fabry Disease$320,056
R01 · FY2011 · DK · contact PI
The Pharmacological Treatment of Fabry Disease$356,733
R01 · FY2010 · DK · contact PI
Lysosomal phospholipase A2 in autoimmune disease$339,461
R01 · FY2010 · AR · contact PI
The Pharmacological Treatment of Fabry Disease$360,336
R01 · FY2009 · DK · contact PI
The Pharmacologic Treatment of Fabry Disease$292,230
R01 · FY2008 · DK · contact PI
The Pharmacologic Treatment of Fabry Disease$298,431
R01 · FY2007 · DK · contact PI
The Pharmacologic Treatment of Fabry Disease$311,297
R01 · FY2006 · DK · contact PI
The Pharmacologic Treatment of Fabry Disease$323,074
R01 · FY2005 · DK
THE PHARMACOLOGIC TREATMENT OF FABRY DISEASE$274,155
R01 · FY2003 · DK
THE PHARMACOLOGIC TREATMENT OF FABRY DISEASE$313,823
R01 · FY2002 · DK
THE PHARMACOLOGIC TREATMENT OF FABRY DISEASE$304,993
R01 · FY2001 · DK
THE PHARMACOLOGIC TREATMENT OF FABRY DISEASE$332,886
R01 · FY2000 · DK